Presented at the American College of Neuropsychopharmacology (ACNP) Annual Meeting held December 8-11, 2019 in Orlando, FL
The FDA requires drug developers focused on cognitive improvement in schizophrenia to demonstrate the functional relevance of any improvements with a co-primary measure of functional capacity. The VRFCAT uses a realistic simulated environment to create a series of routine activities of daily living. The FDA requires evidence that co-primary measures shoe strong convergence with at least one of the MATRICS cognitive domains. An essential step is to determine whether components of the VRFCAT should be examined separately or aggregated on the basis of their latent structure.